ZA200704034B - Improved viral purification methods - Google Patents

Improved viral purification methods

Info

Publication number
ZA200704034B
ZA200704034B ZA200704034A ZA200704034A ZA200704034B ZA 200704034 B ZA200704034 B ZA 200704034B ZA 200704034 A ZA200704034 A ZA 200704034A ZA 200704034 A ZA200704034 A ZA 200704034A ZA 200704034 B ZA200704034 B ZA 200704034B
Authority
ZA
South Africa
Prior art keywords
purification methods
improved viral
viral purification
improved
methods
Prior art date
Application number
ZA200704034A
Other languages
English (en)
Inventor
Matthew C Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36202651&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200704034(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of ZA200704034B publication Critical patent/ZA200704034B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA200704034A 2004-10-22 2005-10-21 Improved viral purification methods ZA200704034B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62125704P 2004-10-22 2004-10-22

Publications (1)

Publication Number Publication Date
ZA200704034B true ZA200704034B (en) 2008-08-27

Family

ID=36202651

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200704034A ZA200704034B (en) 2004-10-22 2005-10-21 Improved viral purification methods

Country Status (15)

Country Link
US (1) US7901921B2 (xx)
EP (1) EP1814982B1 (xx)
JP (2) JP4898690B2 (xx)
CN (2) CN101098959A (xx)
AU (1) AU2005297372B2 (xx)
BR (1) BRPI0516221A (xx)
CA (1) CA2584142C (xx)
DK (1) DK1814982T3 (xx)
ES (1) ES2562237T3 (xx)
HK (1) HK1100959A1 (xx)
IL (1) IL182562A0 (xx)
MX (1) MX2007004696A (xx)
SG (1) SG156673A1 (xx)
WO (1) WO2006042414A1 (xx)
ZA (1) ZA200704034B (xx)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0309659A (pt) * 2002-04-30 2005-02-22 Oncolytics Biotech Inc Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso
CA2617600A1 (en) * 2005-08-01 2007-09-07 University Technologies International, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US20080131955A1 (en) * 2006-11-30 2008-06-05 Canon U.S. Life Sciences, Inc. Method of Separating Target DNA from Mixed DNA
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
MX2010008970A (es) * 2008-02-12 2011-05-30 Sanofi Pasteur Ltd Metodo que utiliza cromatografia de intercambio ionico y filtracion en gel para la purificacion de poxvirus.
CN101270350A (zh) * 2008-03-05 2008-09-24 辽宁依生生物制药有限公司 一种提取狂犬病病毒的方法
RU2560976C2 (ru) 2009-05-12 2015-08-20 Трансген Са Способ продуцирования и очистки ортопоксвируса
CN102191226A (zh) * 2010-03-08 2011-09-21 北京清大天一科技有限公司 细胞培养混合物的分离纯化方法
CN102985536B (zh) * 2010-04-14 2017-12-05 Emd密理博公司 生产高效价、高纯度的病毒母液的方法及使用其的方法
TW201233803A (en) 2010-12-02 2012-08-16 Oncolytics Biotech Inc Lyophilized viral formulations
JP6034798B2 (ja) 2010-12-02 2016-11-30 オンコリティクス バイオテク，インコーポレーテッド 液体ウイルス製剤
US20120273424A1 (en) 2011-04-29 2012-11-01 Oncolytics Biotech Inc. Methods of purifying viruses using gel permeation chromatography
CN102628030B (zh) * 2012-01-20 2013-12-04 宁波大学 三疣梭子蟹呼肠孤病毒的鸡胚培养方法
CN103571800B (zh) * 2012-07-27 2018-04-24 江苏康润生物科技有限公司 一种去除疫苗中宿主dna的方法
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
CN106574252B (zh) * 2014-07-24 2021-06-01 扬森疫苗与预防公司 从细胞培养物中纯化脊髓灰质炎病毒的方法
BR112017009497A2 (pt) 2014-11-05 2018-02-06 Voyager Therapeutics, Inc. polinucleotídeos de aadc para o tratamento da doença de parkinson
US10597660B2 (en) 2014-11-14 2020-03-24 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
ES2878451T3 (es) 2014-11-14 2021-11-18 Voyager Therapeutics Inc Polinucleótidos moduladores
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
ES2895148T3 (es) 2015-06-10 2022-02-17 Us Health Procesos para la producción y purificación de composiciones que contienen ácidos nucleicos
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11951121B2 (en) 2016-05-18 2024-04-09 Voyager Therapeutics, Inc. Compositions and methods for treating Huntington's disease
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
CA3035522A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN111108198A (zh) 2017-05-05 2020-05-05 沃雅戈治疗公司 治疗亨廷顿病的组合物和方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
US10851350B1 (en) * 2017-06-27 2020-12-01 Genelux Corporation Bioreactor production of virus from adherent cells
AU2018302016A1 (en) 2017-07-17 2020-02-06 The Regents Of The University Of California Trajectory array guide system
JP7221275B2 (ja) 2017-08-03 2023-02-13 ボイジャー セラピューティクス インコーポレイテッド Ａａｖを送達するための組成物および方法
TWI804518B (zh) 2017-10-16 2023-06-11 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US11603527B2 (en) * 2017-12-27 2023-03-14 Global Life Sciences Solutions Usa Llc Method and kit for viral vector isolation
US20210010028A1 (en) 2018-03-06 2021-01-14 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
EP3793686A1 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
WO2019222444A2 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Directed evolution
JP7315590B2 (ja) 2018-06-12 2023-07-26 クビオ・ホールディングス・リミテッド ウイルスと抗原の精製及び結合
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11529413B2 (en) 2018-06-12 2022-12-20 Kbio Holdings Limited Virus and antigen purification and conjugation
AU2019299861A1 (en) 2018-07-02 2021-01-14 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
CA3104392A1 (en) * 2018-07-04 2020-01-09 Probiogen Ag Method for purifying an enveloped virus
JP2021530548A (ja) 2018-07-24 2021-11-11 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. 遺伝子治療製剤を生産するための系および方法
WO2020072849A1 (en) 2018-10-04 2020-04-09 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
US20220064671A1 (en) 2019-01-18 2022-03-03 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
KR102228267B1 (ko) * 2019-01-25 2021-03-17 바이로큐어 주식회사 Bhk-21 세포를 이용한 바이러스 생산방법
EP3962536A1 (en) 2019-04-29 2022-03-09 Voyager Therapeutics, Inc. Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors
US20220290182A1 (en) 2019-08-09 2022-09-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
EP4022070A1 (en) 2019-08-26 2022-07-06 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2022032153A1 (en) 2020-08-06 2022-02-10 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141377A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN113913397A (zh) * 2021-11-23 2022-01-11 贵州医科大学 一种溶瘤病毒的纯化方法
CN115300621B (zh) * 2022-08-05 2023-12-12 上海生物制品研究所有限责任公司 水痘-带状疱疹减毒活疫苗制备方法和系统
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB896439A (en) 1959-12-28 1962-05-16 Glaxo Lab Ltd Cellulose derivatives useful as anion-exchange materials and their application
DE1182391B (de) 1961-10-14 1964-11-26 Behringwerke Ag Verfahren zur Desaggregation und Reinigung von Viren
US4070453A (en) 1976-06-25 1978-01-24 Syntex (U.S.A.) Inc. Diploid porcine embryonic cell strains, cultures produced therefrom, and use of said cultures for production of vaccines
US4721675A (en) 1982-02-01 1988-01-26 Abbott Laboratories Production of hepatitis A virus in vitro utilizing a persistently virus infected cell culture system
US4559229A (en) 1982-07-20 1985-12-17 Research Foundation Avian proventriculitis vaccine
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPS6344532A (ja) 1986-08-11 1988-02-25 Biseibutsu Kagaku Kenkyusho:Kk 豚のレオウイルス感染症ワクチン
US5948441A (en) 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
US5658779A (en) 1992-03-20 1997-08-19 Ligochem, Inc. Method of adsorbing viruses from fluid compositions
DZ1706A1 (fr) 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
FR2696748B1 (fr) * 1992-10-14 1994-12-30 Pasteur Merieux Serums Vacc Procédé de préparation d'antigènes et de vaccins de l'hépatite A (HAV).
US5614413A (en) 1993-07-01 1997-03-25 The Uab Research Foundation Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
US6686200B1 (en) * 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
SK147696A3 (en) 1994-05-16 1997-08-06 Merck & Co Inc Isolated and purified protein of papillomavirus, a capside, a viral particle, pharmaceutical composition comprising its, a method of making them and their use
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
CA2625279A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
TR199802783T2 (xx) * 1996-07-02 1999-03-22 Connaught Laboratories Limited �ok de�erli DTP polyo a��lar.
EP1760151B1 (en) 1996-11-20 2012-03-21 Crucell Holland B.V. Adenovirus compositions obtainable by an improved production and purification method
DE69739961D1 (de) 1996-12-13 2010-09-23 Schering Corp Methoden zur Virus-Reinigung
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6214333B1 (en) 1997-07-08 2001-04-10 Texas Heart Institute Vasoprotective recombinant adenovirus vector containing a human TFPI gene
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
DE19812940A1 (de) * 1998-03-24 1999-10-07 Medigene Ag Formulierung mit Papillomavirus-spezifischem Protein, seine Herstellung und Verwendung
IL143381A0 (en) * 1998-12-31 2002-04-21 Aventis Pharma Sa Method for separating viral particles
US6376210B1 (en) * 1999-07-06 2002-04-23 General Atomics Methods and compositions for assaying analytes
CN1139656C (zh) * 1999-11-17 2004-02-25 本元正阳基因技术股份有限公司 一种快速高效分离和纯化重组腺病毒相关病毒的方法和用途
US20040241176A1 (en) * 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
DE60135983D1 (de) 2000-05-31 2008-11-13 Novartis Vaccines & Diagnostic Verfahren zur reinigung von alphaviralen replikon partikeln
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
KR100519902B1 (ko) * 2000-10-27 2005-10-10 에프. 호프만-라 로슈 아게 가용성 피롤로퀴놀린 퀴논 의존성 글루코오스 디히드로게나아제의 변이체
BR0207527A (pt) 2001-03-16 2004-02-25 Oncolytics Biotech Inc Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso
BR0309659A (pt) 2002-04-30 2005-02-22 Oncolytics Biotech Inc Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso
JP4268384B2 (ja) * 2002-08-07 2009-05-27 財団法人阪大微生物病研究会 日本脳炎ウイルス抗原及びその製造方法

Also Published As

Publication number Publication date
AU2005297372B2 (en) 2010-08-26
MX2007004696A (es) 2007-06-14
CA2584142A1 (en) 2006-04-27
SG156673A1 (en) 2009-11-26
ES2562237T3 (es) 2016-03-03
CN105062980A (zh) 2015-11-18
JP4898690B2 (ja) 2012-03-21
JP2012040026A (ja) 2012-03-01
AU2005297372A1 (en) 2006-04-27
EP1814982B1 (en) 2015-12-23
DK1814982T3 (en) 2016-03-21
CN101098959A (zh) 2008-01-02
CA2584142C (en) 2011-11-29
US20060088869A1 (en) 2006-04-27
IL182562A0 (en) 2007-07-24
EP1814982A1 (en) 2007-08-08
HK1100959A1 (en) 2007-10-05
JP2008516616A (ja) 2008-05-22
BRPI0516221A (pt) 2008-08-26
WO2006042414A1 (en) 2006-04-27
US7901921B2 (en) 2011-03-08
EP1814982A4 (en) 2009-03-04

Similar Documents

Publication Publication Date Title
IL182562A0 (en) Improved viral purification methods
HK1070670A1 (en) Improved viral purification methods
EP1773403A4 (en) VIRAL ADJUVANZIA
EP1718608A4 (en) VIRAL POLYMERASE HEMMER
DE502005003298D1 (en) Ls
GB0524283D0 (en) Regeneration means
GB0503942D0 (en) Purification process
GB0416487D0 (en) Modified virus
GB0523257D0 (en) Purification process
SG119251A1 (en) Methods
PL1763398T3 (pl) Środki do barwienia podłoży
GB0403629D0 (en) Methods
GB0423552D0 (en) Methods
GB0408424D0 (en) Viral assay
GB0411530D0 (en) Purification device
GB0413566D0 (en) Purification process
AU158102S (en) Purification unit
GB0520800D0 (en) Viral treatment
GB0415757D0 (en) Methods
GB0419712D0 (en) Purification filters
GB0508061D0 (en) RNA viruses
GB0508060D0 (en) RNA viruses
GB0317218D0 (en) Purification means
GB0413798D0 (en) Novel methods
GB0427706D0 (en) Novel methods